16305 36TH AVENUE N, MINNEAPOLIS, MN
Appoints David Gryska To Its Board Of Directors
Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
Investor Presentation
Amended material disclosure
Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Prospectus filed pursuant to Rule 305(b)(2)
Free Writing Prospectus
Amended Form D Notice of Exempt Offering of Securities